{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:19:40Z","timestamp":1789341580015,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81901283"],"award-info":[{"award-number":["81901283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81801254"],"award-info":[{"award-number":["81801254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171246"],"award-info":[{"award-number":["82171246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Sailing Program","award":["22YF1440200"],"award-info":[{"award-number":["22YF1440200"]}]},{"name":"the Shanghai Rising-Star Program","award":["22QA1405700"],"award-info":[{"award-number":["22QA1405700"]}]},{"name":"Key Field Research and Development Program of Guangdong Province","award":["2018B030337001"],"award-info":[{"award-number":["2018B030337001"]}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR3012A"],"award-info":[{"award-number":["SHDC2020CR3012A"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFE0210100"],"award-info":[{"award-number":["2022YFE0210100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01299-7","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:47:02Z","timestamp":1772488022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gut ecosystem dysfunction in parkinson\u2019s disease: deciphering faecal metabolome-metagenome links for novel diagnostic panels"],"prefix":"10.1038","volume":"12","author":[{"given":"Yiwei","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(05)70801-1","volume":"365","author":"Z-X Zhang","year":"2005","unstructured":"Zhang, Z.-X. et al. Parkinson\u2019s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365, 595\u2013597 (2005).","journal-title":"Lancet"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease. JAMA 323, 548 (2020).","journal-title":"JAMA"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469\u20131480 e1412 (2016).","journal-title":"Cell"},{"key":"1299_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0428-y","volume":"9","author":"JR Bedarf","year":"2017","unstructured":"Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson\u2019s disease patients. Genome Med. 9, 39 (2017).","journal-title":"Genome Med."},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/mds.28119","volume":"35","author":"H Nishiwaki","year":"2020","unstructured":"Nishiwaki, H. et al. Meta-analysis of gut dysbiosis in Parkinson\u2019s disease. Mov. Disord. 35, 1626\u20131635 (2020).","journal-title":"Mov. Disord."},{"key":"1299_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41588-018-0135-7","volume":"50","author":"J Zierer","year":"2018","unstructured":"Zierer, J. et al. The fecal metabolome as a functional readout of the gut microbiome. Nat. Genet. 50, 790\u2013795 (2018).","journal-title":"Nat. Genet."},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2174\/138920211797248619","volume":"12","author":"J Tang","year":"2011","unstructured":"Tang, J. Microbial metabolomics. Curr. Genomics 12, 391\u2013403 (2011).","journal-title":"Curr. Genomics"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jfma.2018.09.007","volume":"118","author":"MX Chen","year":"2019","unstructured":"Chen, M. X., Wang, S. Y., Kuo, C. H. & Tsai, I. L. Metabolome analysis for investigating host-gut microbiota interactions. J. Formos. Med. Assoc. 118, S10\u2013S22 (2019).","journal-title":"J. Formos. Med. Assoc."},{"key":"1299_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/mds.29063","volume":"37","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. Parkinson\u2019s disease is associated with impaired gut-blood barrier for short-chain fatty acids. Mov. Disord. 37, 1634\u20131643 (2022).","journal-title":"Mov. Disord."},{"key":"1299_CR10","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"SJ Chen","year":"2022","unstructured":"Chen, S. J. et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with parkinson disease. Neurology 98, e848\u2013e858 (2022).","journal-title":"Neurology"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66\u201372 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1299_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2018.05.007","volume":"53","author":"A Lin","year":"2018","unstructured":"Lin, A. et al. Gut microbiota in patients with Parkinson\u2019s disease in southern China. Parkinsonism Relat. Disord. 53, 82\u201388 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2018.02.016","volume":"70","author":"Y Qian","year":"2018","unstructured":"Qian, Y. et al. Alteration of the fecal microbiota in Chinese patients with Parkinson\u2019s disease. Brain, Behav., Immun. 70, 194\u2013202 (2018).","journal-title":"Brain, Behav., Immun."},{"key":"1299_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Gut Microbial Ecosystem in Parkinson Disease: new Clinicobiological Insights from Multi-Omics. Ann. Neurol. 89, 546\u2013559 (2021).","journal-title":"Ann. Neurol."},{"key":"1299_CR15","doi-asserted-by":"crossref","unstructured":"Vascellari, S. et al. Gut microbiota and metabolome alterations associated with Parkinson\u2019s disease. mSystems 5, (2020).","DOI":"10.1128\/mSystems.00561-20"},{"key":"1299_CR16","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1053\/j.gastro.2019.11.301","volume":"158","author":"IB Jeffery","year":"2020","unstructured":"Jeffery, I. B. et al. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology 158, 1016\u20131028 e1018 (2020).","journal-title":"Gastroenterology"},{"key":"1299_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","volume":"32","author":"TG Oh","year":"2020","unstructured":"Oh, T. G. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 32, 878\u2013888 e876 (2020).","journal-title":"Cell Metab."},{"key":"1299_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jpba.2017.02.008","volume":"138","author":"M Yu","year":"2017","unstructured":"Yu, M. et al. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC\/MS-based metabolomics. J. Pharm. Biomed. Anal. 138, 231\u2013239 (2017).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"1299_CR19","doi-asserted-by":"crossref","unstructured":"Li, P. et al. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson\u2019s disease. Metabolites 11, (2021).","DOI":"10.3390\/metabo11010029"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/brain\/awaa201","volume":"143","author":"Y Qian","year":"2020","unstructured":"Qian, Y. et al. Gut metagenomics-derived genes as potential biomarkers of Parkinson\u2019s disease. Brain 143, 2474\u20132489 (2020).","journal-title":"Brain"},{"key":"1299_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-019-0157-3","volume":"16","author":"B Dalile","year":"2019","unstructured":"Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 16, 461\u2013478 (2019).","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1299_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-020117-043559","volume":"15","author":"W Van Treuren","year":"2020","unstructured":"Van Treuren, W. & Dodd, D. Microbial contribution to the human metabolome: implications for health and disease. Annu. Rev. Pathol.: Mech. Dis. 15, 345\u2013369 (2020).","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"1299_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/mds.28052","volume":"35","author":"MS Cirstea","year":"2020","unstructured":"Cirstea, M. S. et al. Microbiota composition and metabolism are associated with gut function in Parkinson\u2019s disease. Mov. Disord. 35, 1208\u20131217 (2020).","journal-title":"Mov. Disord."},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26307","volume":"30","author":"A Keshavarzian","year":"2015","unstructured":"Keshavarzian, A. et al. Colonic bacterial composition in Parkinson\u2019s disease. Mov. Disord. : Off. J. Mov. Disord. Soc. 30, 1351\u20131360 (2015).","journal-title":"Mov. Disord. : Off. J. Mov. Disord. Soc."},{"key":"1299_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.105187","volume":"160","author":"Z Yan","year":"2021","unstructured":"Yan, Z. et al. Alterations of gut microbiota and metabolome with Parkinson\u2019s disease. Micro. Pathog. 160, 105187 (2021).","journal-title":"Micro. Pathog."},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41531-022-00312-z","volume":"8","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 48 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/mdc3.12082","volume":"1","author":"J DiFrancisco-Donoghue","year":"2014","unstructured":"DiFrancisco-Donoghue, J., Rabin, E., Lamberg, E. M. & Werner, W. G. Effects of tyrosine on parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Mov. Disord. Clin. Pr. 1, 348\u2013353 (2014).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","volume":"99","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Association between microbial tyrosine decarboxylase gene and levodopa responsiveness in patients with Parkinson disease. Neurology 99, e2443\u2013e2453 (2022).","journal-title":"Neurology"},{"key":"1299_CR29","doi-asserted-by":"crossref","unstructured":"Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, (2019).","DOI":"10.1126\/science.aau6323"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ene.14470","volume":"27","author":"FJ Jimenez-Jimenez","year":"2020","unstructured":"Jimenez-Jimenez, F. J., Alonso-Navarro, H., Garcia-Martin, E. & Agundez, J. A. G. Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson\u2019s disease: review and meta-analysis. Eur. J. Neurol. 27, 2336\u20132347 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1299_CR31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.parkreldis.2015.05.016","volume":"21","author":"Q Tong","year":"2015","unstructured":"Tong, Q. et al. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson\u2019s disease are associated with nonmotor symptoms. Parkinsonism Relat. Disord. 21, 882\u2013887 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1299_CR32","doi-asserted-by":"publisher","first-page":"e101763","DOI":"10.1371\/journal.pone.0101763","volume":"9","author":"E Olivola","year":"2014","unstructured":"Olivola, E. et al. Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. PLoS ONE 9, e101763 (2014).","journal-title":"PLoS ONE"},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0006-8993(94)91761-2","volume":"639","author":"K Shannak","year":"1994","unstructured":"Shannak, K. et al. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res. 639, 33\u201341 (1994).","journal-title":"Brain Res."},{"key":"1299_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1152","volume":"13","author":"A Augustin","year":"2023","unstructured":"Augustin, A. et al. Faecal metabolite deficit, gut inflammation and diet in Parkinson\u2019s disease: Integrative analysis indicates inflammatory response syndrome. Clin. Transl. Med. 13, e1152 (2023).","journal-title":"Clin. Transl. Med."},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","volume":"14","author":"Y Shao","year":"2019","unstructured":"Shao, Y. & Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol. Neurodegener. 14, 3 (2019).","journal-title":"Mol. Neurodegener."},{"key":"1299_CR36","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1021\/acs.jproteome.8b00224","volume":"17","author":"SF Graham","year":"2018","unstructured":"Graham, S. F. et al. Biochemical profiling of the brain and blood metabolome in a mouse model of prodromal Parkinson\u2019s disease reveals distinct metabolic profiles. J. Proteome Res. 17, 2460\u20132469 (2018).","journal-title":"J. Proteome Res."},{"key":"1299_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnagi.2018.00051","volume":"10","author":"D Stoessel","year":"2018","unstructured":"Stoessel, D. et al. Promising metabolite profiles in the plasma and CSF of early clinical Parkinson\u2019s disease. Front Aging Neurosci. 10, 51 (2018).","journal-title":"Front Aging Neurosci."},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.parkreldis.2015.09.009","volume":"21","author":"H Luan","year":"2015","unstructured":"Luan, H. et al. Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 1371\u20131372 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.26992","volume":"32","author":"F Burte","year":"2017","unstructured":"Burte, F. et al. Metabolic profiling of Parkinson\u2019s disease and mild cognitive impairment. Mov. Disord. 32, 927\u2013932 (2017).","journal-title":"Mov. Disord."},{"key":"1299_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1299_CR41","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"1299_CR42","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1021\/acs.analchem.0c04686","volume":"93","author":"G Xie","year":"2021","unstructured":"Xie, G. et al. A Metabolite array technology for precision medicine. Anal. Chem. 93, 5709\u20135717 (2021).","journal-title":"Anal. Chem."},{"key":"1299_CR43","unstructured":"Ho, T. K. (1995) Random Decision Forest. In Proceedings of the 3rd International Conference on Document Analysis and Recognition, Montreal, 14\u201316 August 1995 278\u2013282 (1995)."},{"key":"1299_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1023\/A:1022627411411","volume":"20","author":"C Cortes","year":"1995","unstructured":"Cortes, C. & Vapnik, V. Support-vector networks. Mach. Learn. 20, 273\u2013297 (1995).","journal-title":"Mach. Learn."},{"key":"1299_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/FI-2010-288","volume":"101","author":"M Kursa","year":"2010","unstructured":"Kursa, M., Jankowski, A. & Rudnicki, W. Boruta\u2014a system for feature selection. Fundam. Inform. 101, 271\u2013285 (2010).","journal-title":"Fundam. Inform."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01299-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:05:38Z","timestamp":1775743538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01299-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the authors have approved the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"91"}}